Navigation Links
CBDM.T, The Market and Business Intelligence Company Reviews The Enzyme Market

According to CBDM.T®, The market and business intelligence company, the enzyme market is significant and estimated at €3.4 billion with an annual growth of about 6.5 to 10%. Enzymes are sold in many different industry segments. These segments are Detergents, Food, Feed, Technical, Pharmaceutical, Microorganisms and Biofuels.

Paris (PRWEB) July 8, 2008 -- According to CBDM.T®, The market and business intelligence company, the enzyme market is significant and estimated at € 3.4 billion with an annual growth of about 6.5 to 10%. Enzyme products such as Insulin were the first biotech product marketed in the 70's. While enzymes are present everywhere and come in thousands of different forms, there are still only about 25 of them which have actually been industrialised and commercialised. They include Amylase, Proteinase, Lipase, Cellulase, Glycomylase, Glucose Isomerase, Chymosin, Lactase, Pullulanase and Xylanase.

Some countries have a better developed enzyme industry than others, so descriptions of these countries and the nature of the environment they provide for upcoming businesses is given in this market review. In some countries, the industry was developed with support from the state from as early as the 1980's. These are countries such as Denmark, USA and Brazil. The real breakthrough in the industry happened during the 1970s. A new technology was developed, recombinant biotechnology, and this permitted biochemists to create and modify molecules at an unprecedented level.

Enzymes are sold in many different industry segments. These segments are Detergents, Food, Feed, Technical, Pharmaceutical, Microorganisms and Biofuel. For example in the feed industry, enzymes help pigs or chickens digest their food better, which in the end helps producing better meat, while using smaller amounts of fodder. These segments are thoroughly described in this enzyme market review, looking at market sizes, growth and, while looking at global and key market drivers for each segment are also identified and analyzed.

Biofuel is dealt with in particular depth, since it is a potentially large segment for the future. The global Biofuel market (biodiesel derived from vegetable oil and ethanol derived from sugar or starch) was estimated to be worth €25 billion in 2007.

Biocatalysis is also more frequently applied by chemical companies, since it is the pertinent technology for the manufacturing of chiral drugs and sometimes for oil-based chemistry substitution. Enzymes are a key element in performing biocatalysis (biocatalysts are in fact enzymes). This means that biocatalysis will probably be a significant segment in the future enzyme market. This promising market segment is difficult to estimate. But we know that this market segment will affect the market of catalysts estimated by CBDM.T® at more than $7 billion."This explains why some enzyme producers such as Novozymes are investing more and more in the development of this field" says Philippe Tramoy, managing partner.

Key players are: Novozymes, Danisco, Genencor, Verenium, Syngenta, Monsanto, Dyadic, Codexis, Cargill, Diversa, ADM, Dow, IEP, DSM, Genzyme, BASF, Altus, Biocon, Henkel, Roche, Sanofi, Solvay, Direvo, Maxygen...

If you need more information about CBDM.T® Enzyme Market Review, please contact us at contact @

CBDM.T® - Market and Business Intelligence - is a market and business intelligence company with offices in France and in Israel. As an advisory services company, CBDM.T® boosts companies to develop revenue and growth by providing business and marketing services in the life science and biotech markets (market survey, market scouting, business development and strategic supports).

For more information:
CBDM.T® Market and Business Intelligence
88-90 rue de la Mare
Fr-75020 Paris - France
Tel : +33 1 4474 7957
Email : contact @
Web site : CBDM.T®

CBDM.T® - Israel
POBox 6235
Netanya - 42490 - Israel
Tel: +972 52 3316190


Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
2. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
3. Ranbaxy Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets
4. Competition Alive in the Global Spine Market
5. In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict
6. Aortic Stent Grafts Will Boost Canadian and Japanese Peripheral Vascular Markets
7. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
8. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
9. Mega-Brand Success: Effective Market Strategy and Tactics
10. Bioheart, Inc. to Transfer to Nasdaq Capital Market
11. GE Energy to market SNS-developed detector electronics system
Post Your Comments:
Related Image:
CBDM.T, The Market and Business Intelligence Company Reviews The Enzyme Market 
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group announced the opening ... the cities of Arica and Iquique in northern Chile. The facilities are part of GSCG’s ... most advanced protocols and techniques in stem cell medicine to patients from around the world. ...
(Date:11/30/2015)... , Nov. 30, 2015 Harvard ... ), a biotechnology company developing bioengineered organ implants ... written notification from The NASDAQ Stock Market that ... price requirements. The letter noted that as a ... common stock having exceeded $1.00 per share for ...
(Date:11/30/2015)... DIEGO , Nov. 30, 2015 Human ... that the company has acquired Cypher Genomics, Inc., a ... robust human genomic interpretation software solutions. The ... will join HLI including Cypher CEO and Co-founder, Ashley ... of HLI,s Pediatric Business.  Financial details of the deal ...
(Date:11/30/2015)... and MAGDEBURG, Germany , November ... NeuroRehabilitation (ECNR) in Vienna, Austria ... European Congress of NeuroRehabilitation (ECNR) in Vienna, ... --> NovaVision, a wholly owned subsidiary of Vycor Medical, ... version of its Internet-delivered NovaVision Therapy Suite at the ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
(Date:11/9/2015)... Calif. , Nov. 9, 2015  Synaptics Inc. ... interface solutions, today announced broader entry into the automotive ... solutions that match the pace of consumer electronics human ... biometric sensors are ideal for the automotive industry and ... Europe , ...
Breaking Biology News(10 mins):